Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

The majority of the drugs for Corneal Ulcer are in the early stages of development and in coming years the market is expected to grow.

Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) -- Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

The majority of the drugs for Corneal Ulcer are in the early stages of development and in coming years the market is expected to grow.

DelveInsight’s ‘Corneal Ulcer Pipeline Insights’ report provides the current treatment landscape and rich analysis of pipeline therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents.

Some of the key pointers from the Corneal Ulcer Pipeline report:

• Corneal Ulcer Pipeline report offers a rich analysis of 6+ key pharma companies and 6+ key therapies.

• Corneal Ulcer pipeline comprises therapies in different stages of trials such as SREC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, among others.

• Key pharma companies working to make the Corneal Ulcer pipeline robust include Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, among others.

• FDA granted Orphan Drug Designation to Recordati Rare Diseases investigational product REC 0559 for the treatment of neurotrophic keratitis.

Discover more about the pharma company and therapy expected to grab maximum share by requesting sample report @ Corneal Ulcer Emerging Therapies and Forecast

Corneal Ulcer: Overview

Corneal Ulcer, also known as Keratitis, is characterized by damage or loss of the epithelial layer associated with infiltration of the underlying corneal stroma.

Whilst the treatment of refractory corneal ulcers is challenging, it is essential that they are resolved as they can quickly endanger the anatomical integrity of the ocular surface or the transparency of the cornea.

Discover more about disease outlook, available therapies, and emerging drugs, visit Corneal Ulcer Pipeline Analysis

Corneal Ulcer Drug Pipeline Assessment

Drug	Company	Phase	MoA	RoA
REC 0559	Recordati/Mime Tech	Phase II	Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists	Eye drop solution
OC01	Oyster Point Pharma	Preclinical	Alpha4 beta2 nicotinic receptor agonists	NA
CSB-001	Claris Biotherapeutics	Phase I/II	NA	Ophthalmic Solution
BD-111	Shanghai BDgene	Phase I/II	Undefined mechanism	corneal injection
NRO-1	Neuroptika	Phase I	Glial cell line-derived neurotrophic factor agonists	Topical
Rose bengal sodium	Provectus Biopharmaceuticals	Preclinical	Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants; Interferon modulators; Interleukin 17 modulators; Interleukin-22 modulators	Topical

Request for Sample to know more @ Corneal Ulcer Pipeline Analysis, Key Companies, and Futuristic Trends

Corneal Ulcer Therapeutics Assessment

The Corneal Ulcer Pipeline report lays down a comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action (MoA).

By Product Type

• Mono

• Combination

By Stage

• Discovery

• Pre-clinical

• IND

• Phase I

• Phase II

• Phase III

• Pre-registration

By Molecule Type

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

By Route of Administration

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

• Molecule Type

By Mechanism of Action

• Nerve growth factor receptor agonists

• Glial cell line-derived neurotrophic factor agonists

• Alpha4 beta2 nicotinic receptor agonists

• Autophagy inhibitors

• Cell membrane modulators

• Autophagy inhibitors

By Targets

• Nerve growth factor receptor

• Glial cell line-derived neurotrophic factor

• Alpha4 beta2 nicotinic receptor

Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions

Scope of the Corneal Ulcer Pipeline Report

Coverage: Global
Key Players: Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, OcuNexus Therapeutics, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc., Dobecure, Editas medicine, and others.
Key Corneal Ulcer Pipeline Therapies: REC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, and others.

Reach out @ Corneal Ulcer Pipeline: Novel therapies and Emerging technologies

Table of Contents

1	Report Introduction
2	Corneal Ulcer Disease Overview
3	Corneal Ulcer Pipeline Therapeutics
4	Therapeutic Assessment
5	Corneal Ulcer – DelveInsight’s Analytical Perspective
6	In-depth Commercial Assessment
7	Corneal Ulcer Collaboration Deals
8	Corneal Ulcer Therapeutic Products in Clinical Stage
9	Corneal Ulcer Therapeutic Products in Non-clinical Stage
10	Corneal Ulcer Therapeutics Pipeline Analysis
11	Inactive Corneal Ulcer Pipeline Products
12	Corneal Ulcer Key Companies
13	Corneal Ulcer Key Products
14	Corneal Ulcer- Unmet Needs
15	Corneal Ulcer Market Drivers and Barriers
16	Corneal Ulcer- Future Perspectives and Conclusion
17	Corneal Ulcer Analyst Views
18	Appendix
19	Report Methodology
20	Consulting Services
21	Disclaimer
22	About DelveInsight

Learn more about the report offerings @ Corneal Ulcer Emerging Therapies, Treatments and Ongoing Clinical Trials

Related Reports
Corneal Ulcer Market
DelveInsight's "Corneal Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report.
Peptic Ulcer Hemorrhage Market
DelveInsight's "Peptic Ulcer Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report.
Varicose Ulcer Market
DelveInsight's " Varicose Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report.
Venous Leg Ulcer Market
DelveInsight's "Venous Leg Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report.

Related Posts
Global Burden of Cytomegalovirus Seroprevalence
Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com